GHK-Cu for Hair: What the Follicle Research Reports

What is GHK-Cu, and why do people use it for hair?

GHK-Cu is the copper-bound form of a small natural human peptide, glycyl-L-histidyl-L-lysine, and the hair interest comes from its known effects on skin repair and blood-vessel growth.

The peptide backbone is GHK: glycine, histidine, and lysine. It binds copper tightly, and the biologically active form in most research is the copper complex, written GHK-Cu. GHK is a real molecule your body makes. It circulates in plasma, and the level falls with age, from about 200 ng/mL around age 20 to about 80 ng/mL by age 60 (Pickart et al., BioMed Res Int 2015, PMID 26236730). Because GHK-Cu is well studied for waking up repair processes in skin, people reason that a follicle, which is a small skin organ, might respond in a similar way. That reasoning is fair as a hypothesis. It is not the same as proof, and this page keeps those two things separate.

For the full picture of the molecule beyond hair, see /ghk-cu. For the wider family of copper-binding peptides, see /copper-peptides.

What does research report on GHK-Cu for hair?

The honest answer: direct GHK-Cu hair data in people is very limited, and the clearest laboratory follicle result is from a sibling copper peptide, AHK-Cu, not GHK-Cu itself.

Start with the strongest single study, and note the peptide carefully. Pyo et al. (Arch Pharm Res 2007, PMID 17703734) tested AHK-Cu, the alanyl-histidyl-lysine copper complex, which is a close cousin of GHK-Cu. Working with human hair follicles kept alive outside the body and with cultured dermal papilla cells (the signaling cells at the base of each follicle that drive the growth cycle), they reported that AHK-Cu at very low concentrations, 10^-12 to 10^-9 molar, stimulated hair follicle elongation and dermal papilla cell proliferation. In the same work the copper complex raised vascular endothelial growth factor (VEGF, a signal for new blood vessels) and lowered transforming growth factor beta-1 (TGF-beta1, a signal linked to the resting and regression phases of the hair cycle), and it shifted cell-survival markers toward less programmed cell death, with a higher Bcl-2/Bax ratio and lower cleaved caspase-3 and PARP. Their conclusion was that the copper peptide promotes human hair follicle growth by supporting dermal papilla cells and reducing their death. That is a real and relevant mechanism, but it is a laboratory result on AHK-Cu, not a clinical outcome and not GHK-Cu.

For GHK-Cu specifically, the hair claim is thinner. The most cited source is a review, where Pickart and Margolina (Int J Mol Sci 2018, PMID 29986520) list, among many proposed actions of GHK-Cu, that it may increase hair growth and thickness and enlarge hair follicle size. Read that for what it is: a summary assertion in a review by the peptide's original discoverer, not a controlled trial with a measured result. You will see confident numbers online, such as specific percentage gains in hair density or head-to-head wins against minoxidil. When traced back, those figures do not map to a verifiable primary human trial of GHK-Cu, so this page does not repeat them.

Why might a copper peptide touch the hair cycle at all? Two mechanism threads are plausible and cited. First, dermal papilla cells run on Wnt/beta-catenin signaling, and that pathway controls their proliferation and their ability to induce hair, shown in human scalp dermal papilla cells independent of any peptide (Xiong et al., J Dermatol 2014, PMID 24354472). Anything that helps dermal papilla cells survive and proliferate, as the AHK-Cu work described, is at least pointing at the right cells. Second, GHK-Cu broadly modulates tissue-repair genes and stimulates blood-vessel and nerve outgrowth in reviews of its gene-expression effects (Pickart et al., BioMed Res Int 2015, PMID 26236730; Pickart and Margolina, Int J Mol Sci 2018, PMID 29986520). Better local blood supply is a reasonable way a follicle could benefit. Both are mechanism, not outcome.

The bottom line for evidence quality: cell and ex-vivo follicle data (mostly on the sibling AHK-Cu) plus review-level assertions for GHK-Cu, with no large modern randomized controlled trial of GHK-Cu for hair loss that this page could verify. Treat GHK-Cu for hair as an area of active interest with early, indirect support, not as an established treatment.

What dosing does hair research report for GHK-Cu?

There is no validated hair-loss dose for GHK-Cu. The numbers below are the concentrations and formats that published research and common cosmetic use describe, not a protocol for you.

The ranges below reflect what published studies and commonly studied research protocols report. This is educational, not a prescription or a personal recommendation.

A note on reading a topical label, shown generically as reference math and not as an instruction: a percentage converts to a concentration once you know the container. A 1% solution is 1 gram per 100 mL, which equals 10 milligrams per mL, or 10,000 micrograms per mL. That is arithmetic for understanding a product label, not guidance to use any particular amount on your scalp. The laboratory follicle work used molar concentrations in a dish, which do not translate directly to what reaches a living follicle from a topical, so no clean scalp dose can be derived from those numbers.

What are the side effects of GHK-Cu for hair use?

For topical scalp use the reported issues are local and mild, and the main hair-specific caution is realistic expectations rather than a documented harm.

Most reported problems with topical GHK-Cu are the ordinary ones for any active applied to skin: redness, mild stinging, dryness, or contact irritation. The reviews describe a long history of cosmetic GHK-Cu use without reports of serious topical toxicity (Pickart et al., BioMed Res Int 2015, PMID 26236730). Because the active complex carries copper, a sensible mechanism-based caution is to avoid piling on many copper-delivering products at once, and to be careful in anyone with a copper-handling disorder such as Wilson's disease, where the body cannot clear copper normally. That is a precaution drawn from how the molecule works, not a reported injury from a hair product.

One point specific to hair worth naming plainly: any routine that shifts follicles into a new growth phase can be followed by a temporary increase in shedding as the cycle resets, which is well described for hair-cycle-active routines in general. There is no clear evidence that a properly formulated copper-peptide topical causes lasting hair loss, but transient shedding when you change a scalp routine is not, by itself, a sign of harm. If shedding is heavy or persistent, that is a reason to talk to a clinician, not to self-diagnose from a label.

For injected or oral research use, the honest statement is that there is no established human safety profile for GHK-Cu at all, and none specific to hair. Purity matters for any injectable research compound, which is why a certificate of analysis is worth reviewing (see /coa). None of this is a safety guarantee.

How long does GHK-Cu last, and does that matter for hair?

There is no clean, agreed pharmacokinetic half-life for a dosed GHK-Cu product, and for a topical hair use the more relevant measure is contact time in the skin, not blood levels.

GHK is a very small tripeptide, and small peptides in blood are generally cleared quickly by peptidases. Most GHK-Cu research is topical or in cell culture, where the question is how long the peptide stays in contact with tissue and how well a formulation delivers it, not how long it circulates. So for a hair context, treat any single half-life number you see quoted with skepticism unless it names a specific measured study. What the follicle work actually depended on was sustained low-concentration exposure in a dish (Pyo et al., PMID 17703734), which says more about steady contact than about a blood half-life.

How does GHK-Cu for hair compare to other options?

GHK-Cu and its copper-peptide siblings are early-stage, mechanism-first candidates for hair, not proven drugs, and they should not be treated as replacements for established hair-loss medicines.

The most direct comparison is within the copper-peptide family itself. The clearest human-follicle laboratory result is for AHK-Cu, not GHK-Cu (Pyo et al., PMID 17703734), so if you read GHK-Cu marketing that cites "the copper peptide hair study," it is often that AHK-Cu paper. They are related but not identical molecules, and the distinction matters for how much confidence to place in GHK-Cu specifically. For how the copper-peptide family is defined and studied, see /copper-peptides, and for GHK-Cu beyond hair, see /ghk-cu.

On copper and the hormone side of hair loss, there is a common online claim that copper inhibits 5-alpha-reductase, the enzyme that makes DHT, the androgen tied to pattern hair loss. Copper ions can inhibit that enzyme in a test tube, but there is no verified clinical evidence that a cosmetic-dose copper-peptide serum meaningfully lowers scalp DHT in people. So GHK-Cu should not be framed as a DHT blocker or a stand-in for the medicines that target that pathway. Where any of these peptides sit in the broader landscape is covered in /what-are-peptides.

GHK-Cu for hair: frequently asked questions

Does GHK-Cu actually regrow hair?

The honest answer is that it is not proven to. Laboratory work on the sibling copper peptide AHK-Cu showed human hair follicle elongation and dermal papilla cell growth in a dish (Pyo et al., Arch Pharm Res 2007, PMID 17703734), and a review lists increased hair growth and thickness among GHK-Cu's proposed actions (Pickart and Margolina, Int J Mol Sci 2018, PMID 29986520). Neither is a controlled human trial of GHK-Cu regrowing hair, so treat regrowth as an open question, not an established result.

Is GHK-Cu or AHK-Cu the peptide in the hair studies?

The clearest human-follicle study used AHK-Cu, the alanyl-histidyl-lysine copper complex, which is a close relative of GHK-Cu (Pyo et al., PMID 17703734). A lot of GHK-Cu hair marketing quietly relies on that AHK-Cu paper. GHK-Cu's own hair support comes mainly from review-level assertions rather than a dedicated trial (Pickart and Margolina, PMID 29986520).

How does a copper peptide affect the hair follicle?

The reported mechanism is on the dermal papilla cells at the base of the follicle. In the AHK-Cu work, the copper peptide raised VEGF, lowered TGF-beta1, and reduced programmed cell death in dermal papilla cells, which supported follicle elongation (Pyo et al., PMID 17703734). Dermal papilla cells depend on Wnt/beta-catenin signaling to proliferate and induce hair (Xiong et al., J Dermatol 2014, PMID 24354472), so helping those cells survive is at least aimed at the right target.

Can GHK-Cu cause hair shedding?

There is no clear evidence that a well-formulated copper-peptide topical causes lasting hair loss. Any routine that resets the hair cycle can be followed by temporary shedding as follicles shift phase, which is general hair-cycle behavior, not a documented toxicity of GHK-Cu. Heavy or persistent shedding is a reason to see a clinician.

Does GHK-Cu block DHT?

Not in any way that is clinically proven. Copper ions can inhibit 5-alpha-reductase in a test tube, but there is no verified human evidence that a cosmetic-dose copper-peptide serum lowers scalp DHT. GHK-Cu should not be treated as a DHT blocker or a replacement for medicines that act on that pathway.

Is there a proven GHK-Cu dose for hair?

No. Research reports concentrations used in cell and ex-vivo experiments, such as 10^-12 to 10^-9 molar for the AHK-Cu follicle work (Pyo et al., PMID 17703734), and reviews describe low-percentage topical formulations for skin (Pickart et al., BioMed Res Int 2015, PMID 26236730). None of that establishes a validated scalp dose for hair loss.

Is GHK-Cu approved for hair loss?

No. GHK-Cu is not an FDA-approved drug for hair loss or for any internal use. Its long track record is as a topical cosmetic ingredient (Pickart et al., PMID 26236730). Anything beyond cosmetic topical use, including injection, has no established human safety profile.